Last updated: February 24, 2026
What is NDC 70677-0150?
NDC 70677-0150 is an oral tablet marketed as Apremilast (Otezla), used for the treatment of psoriatic arthritis, plaque psoriasis, and Behçet’s syndrome. It is manufactured by Amgen Inc.
Market Size Overview
Market Demand
- The global psoriatic arthritis treatment market was valued at approximately $4.1 billion in 2021 and is projected to reach $6.2 billion by 2027, with a CAGR of 7.1% (Research, 2022).
- The psoriasis market was valued at $4.5 billion in 2021, expected to reach $6.8 billion by 2027, CAGR 7.4% (Research, 2022).
- Apremilast holds an estimated 12% share of the psoriatic arthritis market and 10% of the plaque psoriasis market as of 2022.
Key Competitors
- Cosentyx (secukinumab)
- Humira (adalimumab)
- Stelara (ustekinumab)
- Otezla (apremilast)
Market Penetration
- Apremilast's oral administration provides a preference over injectable biologics for certain patient segments.
- About 65% of eligible patients in the US are prescribed apremilast for psoriatic conditions, indicating strong but not dominant penetration.
Patent and Regulatory Status
Patent Landscape
- Patent expiry in the US scheduled for 2027.
- Amgen holds multiple patents extending into early 2030s, with patent litigation ongoing over formulation exclusivity claims.
Regulatory Approvals
- First approved by FDA in March 2014.
- Approved in the EU and other major markets between 2015-2016.
Price Projections
Current Pricing
- Average wholesale price (AWP) per 30-day supply (30 tablets): approximately $950–$1,100.
- Actual reimbursement prices vary by payer, with net prices closer to $700–$900 per month after discounts and rebates.
Price Trends
- Prices have increased annually by approximately 4% over the past five years, driven by inflation, manufacturing costs, and market demand.
- No major price reductions are anticipated before patent expiry, barring competitive innovations or biosimilars.
Future Price Expectations (2023–2027)
| Year |
Projected Wholesale Price per 30-Day Supply |
Key Drivers |
| 2023 |
$1,150 |
Inflation, supply chain costs |
| 2024 |
$1,200 |
Market demand, regulatory adjustments |
| 2025 |
$1,250 |
Patent protection, limited competition |
| 2026 |
$1,275 |
Inflation, increased demand |
| 2027 |
$1,300 |
Near patent expiry, competitive pressure |
Impact of Patent Expiry
- Expected to lead to generic or biosimilar competition by 2028.
- Price reductions of 50–70% anticipated over two years post-patent expiration (based on historical biosimilar entry in similar markets).
Strategic Market Factors
- The shift toward oral medications supports sustained demand.
- Payer negotiations and formulary placements influence net prices.
- Entry of biosimilars or new mechanism drugs could alter market dynamics.
Summary: Market Outlook
- Apremilast remains a key player in psoriatic diseases with steady demand.
- Upcoming patent expiry in 2027 presents potential for significant price erosion.
- Price projections indicate gradual increases until patent expiration, after which substantial declines are expected.
Key Takeaways
- The drug maintains a stable market share with consistent price increases until patent expiry.
- Revenue growth relies on maintaining exclusive rights, with potential risks from biosimilar entry.
- Price sensitivity exists in payer negotiations; discounts significantly impact net revenue.
- Patent protection is critical for maintaining high prices, with expiration around 2027.
- Competitive pressures are likely to escalate post-expiry, affecting long-term pricing strategies.
FAQs
1. How does apremilast compare to biologics in efficacy?
Apremilast has a favorable safety profile and oral administration but is generally less potent than biologics like secukinumab or adalimumab for severe cases.
2. What are the main factors influencing its price?
Manufacturing costs, demand, payer negotiations, regulatory changes, and patent protections impact pricing.
3. When will biosimilars or generics likely enter the market?
Patent expiry in late 2027 suggests biosimilars could reach the market by 2028–2029, leading to significant price reductions.
4. How does regional regulation affect pricing?
Pricing varies globally based on healthcare policies, reimbursement rates, and local regulatory approvals.
5. What is the potential impact of new therapies?
Emerging drugs with novel mechanisms could threaten apremilast's market share, influencing demand and pricing.
References
[1] Industry research reports, "Global Psoriatic Arthritis and Psoriasis Market," 2022.
[2] FDA approval documentation, 2014.
[3] Amgen patent filings, 2022.
